January 6 | 2020
2cureX fortsätter sin IP-expansion genom att säkra ett patent på sitt IndiTreat-test i Australien
Read more
December 13 | 2019
2cureX presenterar framsteg i analysutveckling för IndiTreat® i immuno-onkologi vid ESMO Immuno-Oncology Congress i Genève 11-14 december 2019.
Read more
December 13 | 2019
2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019.
Read more
November 22 | 2019
CORRECTION: 2cureX publishes interim report for the third quarter of 2019
Read more
November 22 | 2019
RÄTTELSE: 2cureX offentliggör delårsrapport för det tredje kvartalet 2019
Read more
November 22 | 2019
2cureX publishes interim report for the third quarter of 2019
Read more
November 22 | 2019
2cureX offentliggör delårsrapport för det tredje kvartalet 2019
Read more
October 15 | 2019
2cureX fortsätter sin IP-expansion genom säkrande av patent på sitt IndiTreat-test i Hong Kong
Read more
October 15 | 2019
2cureX continues its IP expansion by securing a patent on Its IndiTreat test in Hong Kong
Read more
October 8 | 2019
2cureX has made an agreement with one of the largest private cancer hospitals in the Nordic countries
Read more
October 8 | 2019
2cureX har ingått avtal med ett av de största privata cancersjukhusen i Norden
Read more
August 23 | 2019
2cureX offentliggör halvårsrapport för det första halvåret 2019
Read more
August 23 | 2019
2cureX publishes half-year report for the first half of 2019
Read more
July 23 | 2019
2cureX announces that patients are successfully being enrolled in the IndiTreat® pancreatic cancer trial
Read more
July 23 | 2019
2cureX meddelar att patienter framgångsrikt inkluderats i pankreascancerstudie med IndiTreat®
Read more
June 27 | 2019
Last day of trading in BTA 1 in 2cureX AB
Read more
June 27 | 2019
Sista dag för handel med BTA 1 i 2cureX AB
Read more
June 20 | 2019
2cureX appoints Dr. Med. Henrik Harling as Chief Medical Officer
Read more